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A
s a grad student at the University 
of Chicago, Bryan Krantz became 
interested in how proteins fold 
(1, 2). But as a postdoc at Harvard (with 
John Collier), Krantz stopped folding 
proteins, and started unfolding them in-
stead. In particular, he started unfolding 
anthrax toxin (3).
Most people might think twice before 
handling anthrax toxin, let alone spending 
years working with it. But Krantz saw the 
potential of this toxin for revealing how 
proteins unfold before they pass through 
cell membrane channels—a process 
known as translocation.
Anthrax toxin is secreted from the 
bacteria Bacillus anthracis, and its three 
protein components—protective antigen, 
lethal factor, and edema 
factor—assemble on the 
surfaces of target cells. 
The protective antigen 
inserts itself into a cell 
membrane and creates 
a translocase channel, 
which allows the other 
two proteins to enter 
into the cell. Krantz, 
who now runs his own 
laboratory at the Uni-
versity of California, 
Berkeley, is using this 
toxin system to study 
the biophysical mecha-
nisms of translocation 
(4). He believes this 
method of toxin delivery might also be 
used by other pathogens.
HOW AND WHY
What were you like as a kid? Were you 
interested in science then?
I guess I’ve been interested in science 
pretty much since I was a small child. 
My son Zack is the same way now, just 
wanting to know why things are the way 
they are. And I think that naturally leads 
to asking questions about the world.
Was this something your parents 
encouraged?
My mom would go to garage sales and 
pick up books on science; they were called 
“The How and Why Wonder Books.” 
They were old-school books, probably 
from the 1960s. It’d be almost any topic 
you could think of—rocks and volcanoes, 
weather, biology.
I tended to do better in math and sci-
ence classes. Though later in college, I 
managed to take enough English class-
es to double major in English and 
Chemistry, but generally I didn’t do as 
well in English.
When did you realize that you wanted 
to make a career of science?
I had thought about different careers. I was 
very interested in art and architecture for 
a while. I was taking drafting classes and 
things like that in high school. But I even-
tually decided, maybe due to a little bit of 
social pressure, “Oh, I should defi  nitely 
become a physician.”
I ended up going to Emory, a liberal 
arts school, and while I was studying 
biology there, I realized that I could do 
research science as a career. I think I became 
very interested in that during my fi  rst or 
second semester of undergrad, and I began 
to wonder whether I wanted to be a physi-
cian or a research scientist.
I considered doing an MD/PhD pro-
gram. I applied to medical schools and 
was accepted at several, but realized 
that I would rather do just pure re-
search—I felt like I would need that 
kind of freedom to get the most out of 
it. So I waited a year, and then applied 
to grad school.
Are you glad you decided not to go 
down the medical route?
I think so. People advised me that unless 
you’re really determined to do very clini-
cally based research, the medical degree 
is probably not going to help you a lot, 
and it could be a distraction. I would give 
the same advice to anybody. I think it 
was defi  nitely a good move for me.
FINDING PROTEIN FOLDING
After Emory, you went to the University 
of Chicago to study biochemistry.
Yeah, at that point I was interested in bio-
chemistry. I had worked in a laboratory as 
an undergrad on the small protein ubiquitin. 
A laboratory at the University of Chicago 
did work related to what I was doing, so 
I was interested in joining them.
But ultimately, through laboratory 
rotations, I came to work in Tobin Sos-
nick’s laboratory, who studied protein 
folding. We still ended up playing around 
with ubiquitin and studying how ubiquitin 
folded. But really I became interested in 
physical chemistry and biophysics, and it 
seemed like I’d found the best laboratory 
for that.
Your thesis was on protein folding?
Yes. The idea of my thesis was to un-
derstand how small proteins folded and 
unfolded. Once you understood the 
fundamental laws of protein folding, 
you could use that knowledge to predict 
how proteins would fold in the cell, 
even proteins whose structure you did 
not know.
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One area that I worked on was probing 
the diversity of folding pathways. We 
thought that there were many possible 
ways in which a protein can fold, not just 
one central route. So we developed a 
methodology for looking at that. And 
found that indeed some proteins can fold 
via multiple pathways.
INVESTIGATING ANTHRAX
Your interest in protein folding and 
protein transport led you to investigate 
anthrax toxin as a postdoc. Tell me how 
that happened.
I wanted to study something of cellular 
relevance, for myself, but also because there 
was a change in politics at the NIH —there 
was a renewed emphasis on studying bio-
logically interesting problems. That’s how I 
came to study protein transport.
Ultimately, I worked on anthrax toxin 
because I felt like it was an area that was 
understudied for the problem of protein 
transport. And anthrax toxin’s protective 
antigen component exists in a fully water- 
soluble form, making it easy to work with. 
We can treat the toxin with a mildly acidic 
pH condition so that it inserts into a mem-
brane, forming the translocase channel. 
So the system seemed self-contained and 
tractable in terms of developing a model.
Also at that time, around 2001, I thought 
that this could be a reasonable way to 
get my work as a postdoc funded, and 
eventually my fi  rst laboratory funded, but 
I wasn’t thinking that far ahead. I thought 
that the bioterrorism angle would be a 
way to do that. But really, in my laboratory, 
we’re not as interested in bioterrorism as 
we are in protein transport.
Aren’t there less dangerous proteins 
to study?
The anthrax toxin is benign relative to 
tetanus or botulinum toxin, so yes and 
no. Really the system is attractive because 
the experiments themselves are tractable 
biophysically.
Why is anthrax a good model for studying 
protein translocation?
Toxins in general are quite stable and easy 
to work with. And so when we started to 
use the toxin system, we knew that we 
could readily incorporate these protective 
antigen protein channels into artifi  cial 
membranes and use classical electrophysi-
ology to monitor protein translocation. We 
can essentially watch protein translocation 
in real time.
In these types of experiments, pro-
tective antigen channels are inserted 
into membranes. The channels conduct 
cations readily and produce an ionic 
current once inserted. The lethal factor 
and edema factor (the substrate proteins) 
are added to the system, and these proteins 
block the channel. Raising the transmem-
brane potential or creating a pH gradient 
across the membrane then drives the 
substrates across the membrane, and the 
ionic current increases. The change in 
ionic current with time is the transloca-
tion kinetics.
So that opens a door to all kinds of 
biophysical studies that examine the 
translocation mechanism in detail. For 
example, we can mutate the channel and 
determine which residues were critical 
for transport and do kinetic assays that 
compare activities.
What about protein transport interests 
you the most?
The reason I became interested in the ques-
tion originally stemmed from the fact 
that most membranes have quite narrow 
pores, probably as a way to prevent ion 
leakage and so forth. That means the 
proteins that translocate 
through them have to be 
unfolded. And that dy-
namic process is so 
poorly understood. I feel 
like it’s a critical area to 
study, and there are a lot 
of possible directions to 
take it.
We’ve really only 
scratched the surface, 
in terms of biophysical 
studies. We have a 
good idea of how small proteins unfold 
and fold in a test tube, but we don’t 
know how proteins unfold in the cell.
In your laboratory at Berkeley, are you 
still focusing mainly on anthrax?
We’re mainly working on anthrax. We’re 
also getting some other projects started 
involving the outer membranes of bac-
teria, which is the interface between 
pathogen and host.
But right now, since the laboratory’s 
only a couple years old, most of the 
projects still involve anthrax. Because 
it’s a toxin, one might say that its rules 
and laws for protein transport are going 
to be different. And I’d agree that some 
of them probably will be, but I think a 
lot of them are going to be general, and 
why not explore the system that is most 
tractable fi  rst? 
1. Krantz, B.A., and T.R. Sosnick. 2000. 
Biochemistry. 39:11696–11701.
2. Krantz, B.A., and T.R. Sosnick. 2001. 
Nat. Struct. Mol. Biol. 8:1042–1047.
3. Krantz, B.A., et al. 2004. J. Mol. Biol. 
344:739–756.
4. Krantz, B.A., et al. 2006. J. Mol. Biol. 
355:968–979.
Krantz deciphers the steps of the translocation pathway in anthrax toxin.
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